Capmatinib Dihydrochloride Monohydrate is an oral targeted therapy classified as a MET inhibitor, indicated for the treatment of specific types of lung cancer by blocking the MET receptor tyrosine kinase.… Read more
Capmatinib Dihydrochloride Monohydrate is an oral targeted therapy classified as a MET inhibitor, indicated for the treatment of specific types of lung cancer by blocking the MET receptor tyrosine kinase. As a critical pharmaceutical reference standard, this compound is essential for laboratories engaged in rigorous impurity profiling and method validation. The availability of high-quality analytical standards supports the accurate identification and quantification of related substances, including pharmacopeial and non-pharmacopeial impurities, as well as active metabolites. Furthermore, stable isotope labelled compounds are vital tools for researchers performing pharmacokinetic studies and mass spectrometry-based assays. By utilizing these reference materials, pharmaceutical developers can ensure compliance with quality control protocols and maintain consistency throughout the drug development lifecycle, from initial analytical method development to routine batch testing of therapeutic products.